Skip to main content
. Author manuscript; available in PMC: 2022 Mar 21.
Published in final edited form as: J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S253–S262. doi: 10.1093/infdis/jiz301

Table 1.

Pneumococcal Meningitis Cases: Burkina Faso, 2011–2017

2011
2012
2013
Pre-
PCV13
2011–2013
2014
2015
2016
2017
Post-
PCV13
2014–2017
Total
Pneumococcal meningitis cases N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Laboratory-confirmed pneumococcal meningitis casesa 642 462 424 1528 502 551 520 397 1970 3498
Patient age groupb
 <1 year 104 (16) 89 (19) 83 (20) 276 (18) 68 (14) 45 (8) 55 (11) 57 (14) 225 (11) 501 (14)
 1 year 19 (3) 25 (5) 21 (5) 65 (4) 17 (3) 9 (2) 22 (4) 24 (6) 72 (4) 137 (4)
 2–4 years 54 (8) 46 (10) 37 (9) 137 (9) 34 (7) 39 (7) 51 (10) 54 (14) 178 (9) 315 (9)
 5–9 years 134 (21) 97 (21) 81 (19) 312 (20) 113 (23) 141 (26) 119 (23) 74 (19) 447 (23) 759 (22)
 10–14 years 125 (20) 81 (18) 81 (19) 287 (19) 113 (23) 124 (23) 122 (23) 80 (20) 439 (22) 726 (21)
 15–29 years 114 (18) 68 (15) 71 (17) 253 (17) 83 (17) 120 (22) 87 (17) 68 (17) 358 (18) 611 (18)
 ≥30 years 92 (14) 56 (12) 50 (12) 198 (13) 74 (15) 73 (13) 62 (12) 40 (10) 249 (13) 447 (13)
Reported deaths 179 (28) 94 (20) 84 (20) 357 (23) 99 (20) 101 (18) 90 (17) 49 (12) 339 (17) 696 (20)

Abbreviations: CSF, cerebrospinal fluid; PCV13, 13-valent pneumococcal conjugate vaccine.

a

Streptococcus pneumoniae isolated from CSF by culture or detected in CSF by real-time polymerase chain reaction or latex agglutination.

b

Two cases missing age in 2016.